Harrow Q2: record revenue $33.5M (+44% YoY), adj. EBITDA $11.0M (+144%); $69M equity offer, product acquisitions

HARROW, INC.

2023-Q2 EPS reported -$0.36 revenue$59,573,000

Record revenues of $33.5M, up 44% YoY; GAAP net loss of $4.2M.
Record adjusted EBITDA of $11.0M, up 144% YoY; core gross margin improved to 78% from 73%.
Completed $69M common stock offering and expanded Oaktree loan from $100M to $112.5M.
Acquired North American rights to VEVYE (dry eye drug) and Santen portfolio including FLAREX, NATACYN, TOBRADEX ST.
Reaffirmed 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HARROW, INC. reported financial results for the second quarter and six months ended June 30, 2023.

Period: the second quarter and six months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 9, 2023, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended June 30, 2023 and an update on recent corporate events.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

HARROW, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-027344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.